bis(N-diethyl carbamyl)disulphide | 59547-11-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫代羰基化合物
• 英文名称: bis(N-diethyl carbamyl)disulphide
• 英文别名: bis(diethylcarbamoyl) disulfide；Bis(diethylcarbamoyl)disulfide；S-(diethylcarbamoylsulfanyl) N,N-diethylcarbamothioate
• CAS: 59547-11-4
• 化学式: C₁₀H₂₀N₂O₂S₂
• 分子量: 264.413
• InChiKey: RBAXVJRSGWIFEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  91.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  bis(N-diethyl carbamyl)disulphide 生成 乙烯
  参考文献：
  名称：

  CHANDE, M. S.;KULKARNI, M. D., J. INDIAN CHEM. SOC., 1981, 58, N 9, 877-879

  摘要：

  DOI：
• 作为产物：
  描述：

  二硫化四乙基秋兰姆 在 sodium hypochlorite 作用下， 以 水 、 乙腈 为溶剂， 反应 12.0h， 以75%的产率得到bis(N-diethyl carbamyl)disulphide
  参考文献：
  名称：

  Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes

  摘要：

  Fructose-1,6-bisphosphatase (FBPase), as a key rate-limiting enzyme in the gluconeogenesis (GNG) pathway, represents a practical therapeutic strategy for type 2 diabetes (T2D). Our previous work first identified cysteine residue 128 (C128) was an important allosteric site in the structure of FBPase, while pharmacologically targeting C128 attenuated the catalytic ability of FBPase. Herein, ten approved cysteine covalent drugs were selected for exploring FBPase inhibitory activities, and the alcohol deterrent disulfiram displayed superior inhibitory efficacy among those drugs. Based on the structure of lead compound disulfiram, 58 disulfide-derived compounds were designed and synthesized for investigating FBPase inhibitory activities. Optimal compound 3a exhibited significant FBPase inhibition and glucose-lowering efficacy in vitro and in vivo. Furthermore, 3a covalently modified the C128 site, and then regulated the N125-S124-S123 allosteric pathway of FBPase in mechanism. In summary, 3a has the potential to be a novel FBPase inhibitor for T2D therapy. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112500

文献信息

• Isocyanate composition
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0042701A2

  公开（公告）日：1981-12-30

  O isocyanate composition which is superior in stability and reactivity, wherein at least one additive selected from the group consisting of peroxides, sulfur, polysulfides, metal sulfides and halogens is added to a reaction product of organic isocyanate and carbon dioxide in an amount of 0.001 to 10% by weight based on the starting isocyanate.

  O 型异氰酸酯组合物具有更高的稳定性和反应活性，其中至少一种添加剂选自过氧化物、硫磺、多硫化物、金属硫化物和卤素组成的组，添加到有机异氰酸酯和二氧化碳的反应产物中，添加量为起始异氰酸酯的 0.001 至 10%（按重量计）。
• Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
  申请人：——

  公开号：US20030087814A1

  公开（公告）日：2003-05-08

  Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.

  治疗、预防或减少酗酒的组合物和方法，特别是提高患者对需要摄入 ALDH 抑制剂的疗法的依从性的方法，包括施用单胺氧化酶 B 抑制剂的步骤。
• Compositions and methods for treating hepatitis C virus (HCV) infection
  申请人：Holsztynska J. Elzbieta

  公开号：US20050249805A1

  公开（公告）日：2005-11-10

  Provided are compositions and methods for protecting a compound comprising a haloalkylamide moiety from metabolic transformation by hydrolases. In one aspect, the disclosure is directed to increasing the bioavailability and tissue delivery of a anti-HCV compound comprising a haloalkylamide moiety by protecting the compound from inactivation by carboxylesterases. Specific approaches for limiting metabolic transformation include use of carboxylesterase inhibitors to inhibit metabolism of the compound, or use of orally administered compositions designed to deliver the compound to the small intestine or large intestine. Further provided are methods of treating or preventing HCV infection in a subject.

  本发明提供了保护包含卤代烷基酰胺分子的化合物免受水解酶代谢转化的组合物和方法。在一个方面，本公开旨在通过保护包含卤代烷基酰胺分子的抗 HCV 化合物不被羧基酯酶灭活，提高该化合物的生物利用度和组织递送。限制代谢转化的具体方法包括使用羧基酯酶抑制剂抑制化合物的代谢，或使用口服给药组合物将化合物输送到小肠或大肠。此外，还提供了治疗或预防受试者感染 HCV 的方法。
• Chande, M. S.; Kulkarni, M. D., Journal of the Indian Chemical Society, 1981, vol. 58, p. 877 - 879
  作者：Chande, M. S.、Kulkarni, M. D.

  DOI：——

  日期：——
• PHARMACEUTICAL COMPOSITIONS COMPRISING DISULFIRAM FOR INHIBITING ANGIOGENESIS
  申请人：YEDA RESEARCHAND DEVELOPMENT COMPANY, LTD.

  公开号：EP1047416A2

  公开（公告）日：2000-11-02